Palivizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Palivizumab and local guidelines before prescribing.
Antiviral antibody
Mechanism
RSV fusion protein monoclonal antibody.
Uses
RSV prophylaxis in high-risk infants.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reaction, fever, rash.
Interactions
Few.
Contraindications and cautions
Hypersensitivity
Monitoring
Infant respiratory status
Pregnancy and breastfeeding
Not applicable
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Monthly in RSV season.
More from the textbook: uses, cautions and other points
- RSV monoclonal antibody (nirsevimab; palivizumab previously) for high-risk infants.
Paediatrics: Respiratory and heart problems in children - RSV - nirsevimab (long-acting monoclonal antibody) for high-risk infants; palivizumab previously.
Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination - RSV - bronchiolitis in infants (peak November–December), pneumonia in older adults; UK RSV vaccination programme from September 2024 for pregnant women from 28 weeks (protects infants) and older adults from age 75 (check current UKHSA eligibility - the age range is being extended); nirsevimab/palivizumab for high-risk infants.
Microbiology: Virology - structure, replication and important viral infections
Where it is discussed in the book
- Paediatrics: Respiratory and heart problems in children (1 mention)
- Clinical Immunology: Secondary immunodeficiency, the immunocompromised host and vaccination (1 mention)
- Integrated paediatrics chapter (1 mention)
- Microbiology: Virology - structure, replication and important viral infections (1 mention)